DDIT3 and lymphoma: In the safety population, 73 (16·3%) of 447 participants in the R-CHOP group and 68 (15·3%) of 444 in the RB-CHOP group died, with most deaths due to progressive lymphoma (50 [68·5%] of 73 in the R-CHOP group, and 54 [79·4%] of 68 in the RB-CHOP group); nine treatment-related deaths were reported (five [6·8%] of 73 in the R-CHOP group, four [5·9%] of 68 in the RB-CHOP group; appendix p 13).